Literature DB >> 34527630

Mixed Cryoglobulinaemia Vasculitis after Persistent Hepatitis C Virus Eradication.

Margarida Gaudêncio1, Rui Nogueira2, Nuno Afonso2,3.   

Abstract

Mixed cryoglobulinaemia vasculitis (MCV) is a systemic vasculitis of the small and medium-size vessels caused by active hepatitis C (HCV) infection in >80% of cases. Beuthien et al. presented the first case of MCV with undetectable HCV after 10 months of therapy. In the last few years, more authors have described other cases of symptomatic MCV after 1 year of persistent HCV eradication. Here, we present a case report of a 57-year-old man who developed MCV with renal involvement after 3 years of HCV eradication with interferon therapy. LEARNING POINTS: Mixed cryoglobulinaemia can occur after persistent hepatitis C virus eradication.Most cases described in the literature presented mixed cryoglobulinaemia vasculitis (MCV) after 1 year of HCV eradication compared with after 3 years of persistent eradication in our case.The exact mechanism linking HCV and B-cells is not fully understood, but the main factor seems to be the sustained HCV antigenic stimulation of the B-cell compartment. © EFIM 2021.

Entities:  

Keywords:  Mixed cryoglobulinemia; hepatitis C virus; remission; vasculitis

Year:  2021        PMID: 34527630      PMCID: PMC8436841          DOI: 10.12890/2021_002808

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  10 in total

Review 1.  Hepatitis C virus infection.

Authors:  G M Lauer; B D Walker
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

2.  Development of type II mixed cryoglobulinaemic syndrome after effective and persistent hepatitis C virus eradication.

Authors:  L Quartuccio; G De Marchi; M Fabris; S De Vita
Journal:  Rheumatology (Oxford)       Date:  2006-12-13       Impact factor: 7.580

Review 3.  Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.

Authors:  Franco Dammacco; Domenico Sansonno
Journal:  N Engl J Med       Date:  2013-09-12       Impact factor: 91.245

4.  Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders.

Authors:  Domenico Rosa; Giulietta Saletti; Ennio De Gregorio; Francesca Zorat; Consuelo Comar; Ugo D'Oro; Sandra Nuti; Michael Houghton; Vincenzo Barnaba; Gabriele Pozzato; Sergio Abrignani
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-09       Impact factor: 11.205

5.  HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations.

Authors:  V De Re; D Sansonno; M P Simula; L Caggiari; D Gasparotto; M Fabris; F A Tucci; V Racanelli; R Talamini; M Campagnolo; S Geremia; F Dammacco; S De Vita
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

Review 6.  Cryoglobulinaemia.

Authors:  Dario Roccatello; David Saadoun; Manuel Ramos-Casals; Athanasios G Tzioufas; Fernando C Fervenza; Patrice Cacoub; Anna Linda Zignego; Clodoveo Ferri
Journal:  Nat Rev Dis Primers       Date:  2018-08-02       Impact factor: 52.329

Review 7.  Hepatitis C virus and the kidney.

Authors:  Stanislas Pol; Lucia Parlati; Michel Jadoul
Journal:  Nat Rev Nephrol       Date:  2019-02       Impact factor: 28.314

Review 8.  Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review.

Authors:  Kanokwan Boonyapisit; Bashar Katirji
Journal:  Muscle Nerve       Date:  2002-06       Impact factor: 3.217

Review 9.  Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature.

Authors:  Wilke Beuthien; Hans-Ullrich Mellinghoff; Johannes von Kempis
Journal:  Clin Rheumatol       Date:  2005-06-30       Impact factor: 3.650

10.  Hepatitis C mixed cryoglobulinemia with undetectable viral load: A case series.

Authors:  Virginia Kartha; Luisa Franco; Susan Coventry; Kenneth McLeish; Dawn J Caster; Courtney R Schadt
Journal:  JAAD Case Rep       Date:  2018-08-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.